PRIME MEDICINE INC (PRME)
Health Care · genetic engineering / gene editing biotechnology · NASDAQ
Prime Medicine is pioneering a versatile and precise "search-and-replace" gene editing platform to create potentially curative, one-time therapies for severe genetic diseases.
What PRIME MEDICINE INC does
Prime Medicine is a biotechnology company developing a new class of genetic medicines based on its proprietary Prime Editing technology. The company utilizes a modular platform designed to create precise, durable, and potentially curative treatments for diseases caused by genetic mutations, with a current focus on in vivo liver-directed therapies, cystic fibrosis, and ex vivo hematology/oncology applications.
Recent developments
In mid-2026, the company received IND/CTA clearances to initiate a global Phase 1/2 clinical study for PM577a in Wilson disease, with initial data expected in 2027. An arbitration with Beam Therapeutics was resolved in the company's favor, confirming its rights to the PM647 AATD program, which is expected to enter the clinic in late 2026. Additionally, the company's PM359 program for CGD received FDA RMAT designation, and the company is preparing for a potential BLA submission.
From PRIME MEDICINE INC's filing of 2026-08-06.
Themes: gene editing, precision medicine, liver disease, oncology, hematology, genetic diseases
Fundamentals
- Price$3.58 as of 2026-10-08 close
- Market cap$649M as of 2026-07-31 (share count; price 2026-10-08)
- 1-year return-44.5% 2025-10-08 close $6.45 → 2026-10-08 close $3.58
- P/En/a negative earnings
- Net margin-4342.4% FY2025, SEC XBRL
- ROE-166.4% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-02
- Revenue growth (YoY)-17.9% as of 2026-09-02
- Beta2.01 as of 2026-09-02
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How PRME compares in its sector
- net profit marginbottom 10% 430 covered Health Care peers, as of 2026-09-02
- operating marginbottom 10% 417 covered Health Care peers, as of 2026-09-02
- return on equitybottom 10% 510 covered Health Care peers, as of 2026-09-02
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How PRIME MEDICINE INC looks technically
PRIME MEDICINE INC (PRME) is trading 2.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 141 trading days ago — a "death cross", a bearish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 25 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 57, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive). It made a new 20-day high about 2 trading days ago. It is 48.4% below its highest point of the past year. Trading volume is running unusually high — about 2.1× its 30-day average, a sign of heightened interest.
Trend
9
| Distance from the 200-day | it is trading 2.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +2.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $3.26 | $3.26 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.49 | $3.49 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 2.77. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 141 trading days ago — a "death cross", a bearish long-term signal | 141 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 2.5% above | +2.5% |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 25 (a reading of 25+ marks a strong trend) | 24.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 57, neither overbought (above 70) nor oversold (below 30) | 56.9 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($2.77 to $4.02) — its "stochastic" reading is 65 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 64.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive) | 3 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $6.94 | $6.94 |
|---|---|---|
| From the 52-week high | it is 48.4% below its 52-week high (its highest price of the past year) | -48.4% |
| Above the 52-week low | it is 34.1% above its 52-week low (its lowest price of the past year) | +34.1% |
| Below the 52-week high | it is 48.4% below its highest point of the past year | 48.4% |
| Since a 20-day breakout | it made a new 20-day high about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day high about 2 trading days ago | 2 sessions |
| All-time high | its highest closing price on record is $21.73 (set on 2022-11-14) | $21.73 |
| Given back of the 52-week move | over the past year its closes ranged ($2.70 to $6.67), and it has recovered roughly a quarter of its fall from last year’s high — 22% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $5.15 to $5.28. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 22.2% |
| From the all-time high | it is 83.5% below its all-time high | -83.5% |
| Nearest price level | it is sitting right on a support level at $3.57 — a price it turned at five times since 2024-11-25, most recently on 2026-09-22. Since 2024-10-08 it has 8 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.3% |
| All-time low | its lowest closing price on record is $1.11 (set on 2025-05-20) | $1.11 |
| Above the all-time low | it is 222.5% above its all-time low | +222.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 70th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.3082 between its high and its low — about 8.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.3082 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.69 and $3.68 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.69 – $3.19 – $3.68 |
| Typical daily range (% of price) | its price moves about 8.6% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 8.6% |
| Stretch from the 200-day average | it is trading 0.3 daily ranges above its 200-day average price (2.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is running unusually high — about 2.1× its 30-day average, a sign of heightened interest | 2.10× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bullish engulfing | 1 session ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 1 session ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-08 1.8% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -1.8% |
|---|---|---|
| Open gap | it gapped 10.9% above the previous close 2 sessions ago and has not traded back through the level it left behind at 3.21 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +10.9% |
| Gap filled | a 4.0% gap down opened on 2026-10-07 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 1 session ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 0.5 percentage points (the stock gained 0.6% while the market gained 1.0%) | -0.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 26.3 percentage points (the stock lost 22.5% while the market gained 3.8%) | -26.3% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 10.3 percentage points (the stock gained 7.2% while the market gained 17.5%) | -10.3% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 59.5 percentage points (the stock lost 44.5% while the market gained 15.0%) | -59.5% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: trading above its 200-day average, a fresh 20-day high, MACD momentum is positive — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, lagging the market over 6 months — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 12.3% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 1% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $3.53 — a volume-weighted average of daily closes over 188 sessions, not a true tick-by-tick VWAP. | +1.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 7% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $3.34 — a volume-weighted average of daily closes over 45 sessions, not a true tick-by-tick VWAP. | +7.2% |
Price levels it has turned at before
PRME last closed at $3.58 on 2026-10-08. Since 2024-10-08 it has turned at 8 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $3.57 | Support | 0.3% below the last close | turned there five times · 2024-11-25 to 2026-09-22 |
| $3.73 | Resistance | 4.2% above the last close | turned there three times · 2025-07-17 to 2026-01-20 |
| $3.35 | Support | 6.4% below the last close | turned there twice · 2025-01-24 to 2025-02-19 |
| $3.84 | Resistance | 7.2% above the last close | turned there three times · 2024-10-31 to 2026-09-04 |
| $3.29 | Support | 8.2% below the last close | turned there three times · 2025-12-02 to 2026-08-10 |
| $4.04 | Resistance | 12.7% above the last close | turned there twice · 2025-11-20 to 2026-04-23 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $2.77.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 3 trading days, since 2026-10-06.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Pulled back from the 12-month high · Unusually heavy trading volume · Broke out to a new 20-day high · Broke out to a new 20-day high on heavy volume | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.50 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$7.11 range $4.25 – $11.00; median $7.00
Analyst estimates, as of 2026-10-04. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for PRME
- Consensus EPS estimate-$0.2336 next reporting period, as of 2026-10-04
- Estimate change, 30 days-$0.00363 from -$0.23, on 2026-08-30, 35-day window
- Readings revised upward14% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["High dependence on third-party intellectual property licenses; potential loss of rights if license obligations are not met.","Operating history of significant losses and dependence on future capital raises to fund clinical development.","Risks associated with clinical trial outcomes and regulatory approval of a novel, unproven gene editing modality."]
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for PRME — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding PRME as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 32,113,429
- Reported value $118,498,555
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about PRME's institutional holders → See what each manager we track holds →
Short interest (FINRA)
PRME had 32,132,218 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
PRME had 17.7% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 12.31 days to cover at the same settlement.
- Reported short interest (shares) 32,132,218
- Short interest (% of shares outstanding) 17.7%
- Prior settlement (shares) 36,761,940
- Reported change -12.59%
- Days to cover (reported) 12.31
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Beam Therapeutics (BEAM)
- Editas Medicine (EDIT)
- Intellia Therapeutics (NTLA)
- CRISPR Therapeutics (CRSP)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare PRME vs…
PRIME MEDICINE INC is found in…
PRME ranks in…
Frequently asked questions
What does PRIME MEDICINE INC (PRME) do?
Prime Medicine is a biotechnology company developing a new class of genetic medicines based on its proprietary Prime Editing technology. The company utilizes a modular platform designed to create precise, durable, and potentially curative treatments for diseases caused by genetic mutations, with a current focus on in vivo liver-directed therapies, cystic fibrosis, and ex vivo hematology/oncology applications.
What sector is PRIME MEDICINE INC (PRME) in?
PRIME MEDICINE INC (PRME) is classified in the Health Care sector. Its industry is genetic engineering / gene editing biotechnology. It trades on NASDAQ.
Who are PRIME MEDICINE INC's (PRME) competitors?
Notable peers of PRIME MEDICINE INC (PRME) include Beam Therapeutics, Editas Medicine, Intellia Therapeutics and CRISPR Therapeutics. This peer set is informational only — not financial advice.
Is PRIME MEDICINE INC (PRME) overbought or oversold right now?
PRIME MEDICINE INC (PRME) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 57, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on PRME come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.